SeerSEER +36.77%53 Net Current Asset Value is $2.74 as of Mar. 2026, which is 281% above its 10-year median of 0.72. GuruFocus rates SEER with a GF Score™ of 53/100 and a GF Value™ of $2.20 (Fairly Valued). The stock has 3 warning signs investors should review. Among 943 Biotechnology companies, Seer ranks better than 96.39% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Seer's net current asset value per share for the quarter that ended in Mar. 2026 was $2.74.
The historical rank and industry rank for Seer's Net Current Asset Value or its related term are showing as below:
SEER'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.39 Med: 0.72 Max: 7.87
Current: 0.81
During the past 8 years, the highest Price-to-Net-Current-Asset-Value Ratio of Seer was 7.87. The lowest was 0.39. And the median was 0.72.
SEER's Price-to-Net-Current-Asset-Value is ranked better than 96.39% of 943
companies
in the Biotechnology industry
Industry Median: 4.95
vs SEER: 0.81
Seer (NAS:SEER) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Seer Net Current Asset Value Related Terms
Seer Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Seer's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SEER vs CSBR, RLYB, FBIO: Net Current Asset Value Comparison
For the Biotechnology subindustry, Seer's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seer Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seer's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Seer's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $2.74 mean?
Seer (SEER) has a Net Current Asset Value of $2.74 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Seer and its competitors. This is 281% above median its historical median of 0.72. Over the past decade, Seer's Net Current Asset Value has ranged from 0.39 to 7.87. According to the industry distribution chart, Seer ranks #34 out of 943 companies in the Biotechnology industry, placing it in the top 3.6%.
Is Seer's Net Current Asset Value too high?
Seer's current Net Current Asset Value of $2.74 is 281% above median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 7.87. The Biotechnology industry median Net Current Asset Value is 4.95. Seer's value of $2.74 is 44.6% below this industry median. Based on the distribution chart, Seer ranks #34 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Seer has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Seer's Net Current Asset Value compare to CSBR and RLYB?
According to the Biotechnology industry distribution chart, Seer ranks #34 out of 943 companies for Net Current Asset Value. This places Seer in the top 4% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.95. Seer's value of $2.74 is 44.6% below this benchmark. Historically, Seer's own Net Current Asset Value has ranged from 0.39 to 7.87 over the past decade. While the company's 10-year median is 0.72 vs. the industry median of 4.95, Seer has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.95, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seer's current Net Current Asset Value of $2.74 is 44.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Seer and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seer's current Net Current Asset Value is $2.74, which is 281% above median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seer stock overvalued right now?
Based on GuruFocus' analysis, Seer (SEER) is currently considered Fairly Valued. The stock's GF Value™ is $2.20, compared to a current price of $2.22 — trading 0.7% above its estimated fair value. The current Net Current Asset Value is $2.74, which is 281% above median its 10-year median of 0.72 and 44.6% below the Biotechnology industry median of 4.95. Seer's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Seer (SEER), the current Net Current Asset Value is $2.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seer (SEER) Overvalued in 2026?
Based on GuruFocus' analysis, Seer stock appears to be overvalued.
The current stock price of $2.22 is trading 0.7% above its estimated GF Value™ of $2.20.
GuruFocus considers Seer to be Fairly Valued.
Key valuation signals for SEER:
Net Current Asset Value: $2.74 (281% above median its 10-year median of 0.72)
GF Value™: $2.20 vs. price of $2.22 (0.7% above fair value)
Industry Position: 44.6% below the Biotechnology median (#34 of 943)
No single metric tells the full story. See the SEER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
53GF Score
Get the complete analysis for SEER
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEER has been successfully added to your 
